Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will present new data at the General Session & Exhibition of the International Association for Dental Research (IADR), to be held in conjunction with the annual meetings of the American Association for Dental, Oral, and Craniofacial Research (AADOCR) and the Canadian Association for Dental Research (CADR). The biennial gathering of the three organizations will take place March 13-16 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
In two oral presentations and two poster discussions, researchers will present data supporting the clinical effectiveness of several of the Company’s iconic products, including Listerine®1 Cool Mint and Cool Mint Zero Alcohol mouthwashes, Listerine® Clinical Solutions Antiseptic Gum Health Mouthwash, and Listerine® Clinical Solutions Breath Defense Mouthwash. The findings demonstrate improved protection against plaque, a reduced prevalence of gingivitis, and/or fresher breath with the addition of the products to a daily oral hygiene regimen that includes brushing and flossing.
“For clinicians who routinely recommend oral health regimens to patients, it’s important to be aware of the latest evidence to support that recommendation,” said Karina Ribeiro, Global Head of R&D, Essential Health at Kenvue.2 “IADR is a great platform to discuss our latest findings with thousands of the world’s leading scientists, industry professionals, academicians, and practicing healthcare providers. Our researchers look forward to convening with colleagues across the field of oral health to share our commitment to science-backed, care-forward solutions that deliver safe, effective, everyday care.”
Kenvue experts and external research partners including Dr. Kimberly Milleman will present findings from four studies during the conference including:
Plaque-Free Sites in a 12-Week Supervised Mouthrinse/Floss Trial (Milleman KR, et al), presented by lead author Kimberly Ruth Milleman, RDH, BSEd, MS, PhD, Global Clinical Director of Salus Research, Inc., in Indiana.
This randomized trial tested the plaque-controlling efficacy of a flossing and/or brushing regimen with an essential oil mouthwash. In evaluating the percentage of whole-mouth plaque-free sites at weeks 4 and 12, statistically significant differences favored groups whose regimens included mouthwash.
Flossing Time/Technique Competency in Supervised Plaque, Gingivitis Clinical Trial (Bosma ML, et al), presented by author and Kenvue R&D Manager Gabriella John. This 12-week, virtually supervised randomized trial found that training in American Dental Association flossing techniques, coupled with virtual dental hygienist supervision, improved participants’ flossing skills. In addition, it found that an essential oil mouth rinse helped compensate for remaining flossing insufficiencies, ultimately improving gingival health and reducing interproximal plaque.
Efficacy of Essential Oil and Zinc-Containing Mouthrinse on Plaque Microbiome, presented by lead author Kyungrok Min, PhD, Principal Scientist at Kenvue. This study used quantitative microbiome analysis to determine that mouth rinses containing a fixed combination of four essential oils (EO) and zinc were effective in reducing plaque and gingivitis and creating a healthier plaque microbiota.
Mouthrinse Effect on Oral Malodor Using Gas Chromatography/Organoleptic Judges (Milleman J, et al), also presented by lead author Kimberly Ruth Milleman, RDH, BSEd, MS, PhD, Global Clinical Director of Salus Research, Inc., in Indiana. This single-center randomized, placebo-controlled trial confirmed the ability of an experimental mouth rinse to neutralize oral malodor by reducing volatile sulfur compounds, the primary source of bad breath. The mouth rinse contained essential oil, zinc, and an odor-neutralizing technology.
1. Listerine® is a brand of Johnson & Johnson Consumer Inc., a subsidiary of Kenvue.
2. Karina Ribeiro is an employee of Johnson & Johnson Consumer Inc., a subsidiary of Kenvue.
